Insulet Corporation
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain… Read more
Insulet Corporation (PODD) - Total Assets
Latest total assets as of September 2025: $3.03 Billion USD
Based on the latest financial reports, Insulet Corporation (PODD) holds total assets worth $3.03 Billion USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Insulet Corporation - Total Assets Trend (2002–2024)
This chart illustrates how Insulet Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Insulet Corporation - Asset Composition Analysis
Current Asset Composition (December 2024)
Insulet Corporation's total assets of $3.03 Billion consist of 60.6% current assets and 39.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 30.9% |
| Accounts Receivable | $365.50 Million | 11.8% |
| Inventory | $430.40 Million | 13.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $98.50 Million | 3.2% |
| Goodwill | $51.50 Million | 1.7% |
Asset Composition Trend (2002–2024)
This chart illustrates how Insulet Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Insulet Corporation's current assets represent 60.6% of total assets in 2024, a decrease from 96.9% in 2002.
- Cash Position: Cash and equivalents constituted 30.9% of total assets in 2024, down from 96.9% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 4.0% of total assets, an increase from 0.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 13.9% of total assets.
Insulet Corporation Competitors by Total Assets
Key competitors of Insulet Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shanghai Kehua Bio-Engineering Co Ltd
SHE:002022
|
China | CN¥5.17 Billion |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223
|
China | CN¥16.67 Billion |
|
Double Medical Technology Inc
SHE:002901
|
China | CN¥4.55 Billion |
|
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
SHE:002932
|
China | CN¥6.10 Billion |
|
Shinhung
KO:004080
|
Korea | ₩153.50 Billion |
|
UMediC Group Berhad
KLSE:0256
|
Malaysia | RM94.93 Million |
|
Osang Healthcare Co.,Ltd
KQ:036220
|
Korea | ₩287.70 Billion |
|
HansBiomed Corporation
KQ:042520
|
Korea | ₩126.41 Billion |
Insulet Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Insulet Corporation generates 0.67x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Insulet Corporation generates $ 13.55 in net profit.
Insulet Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.87 | 3.64 | 6.01 |
| Quick Ratio | 2.18 | 2.76 | 5.27 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.21 Billion | $ 1.34 Billion | $ 1.04 Billion |
Insulet Corporation - Advanced Valuation Insights
This section examines the relationship between Insulet Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 12.24 |
| Latest Market Cap to Assets Ratio | 5.23 |
| Asset Growth Rate (YoY) | 19.3% |
| Total Assets | $3.09 Billion |
| Market Capitalization | $16.16 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Insulet Corporation's assets at a significant premium ( 5.23x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Insulet Corporation's assets grew by 19.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Insulet Corporation (2002–2024)
The table below shows the annual total assets of Insulet Corporation from 2002 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $3.09 Billion | +19.30% |
| 2023-12-31 | $2.59 Billion | +14.97% |
| 2022-12-31 | $2.25 Billion | +9.87% |
| 2021-12-31 | $2.05 Billion | +9.39% |
| 2020-12-31 | $1.87 Billion | +63.87% |
| 2019-12-31 | $1.14 Billion | +23.06% |
| 2018-12-31 | $928.74 Million | +13.71% |
| 2017-12-31 | $816.74 Million | +78.86% |
| 2016-12-31 | $456.65 Million | +65.98% |
| 2015-12-31 | $275.13 Million | -8.95% |
| 2014-12-31 | $302.16 Million | +4.93% |
| 2013-12-31 | $287.95 Million | +45.39% |
| 2012-12-31 | $198.06 Million | -5.50% |
| 2011-12-31 | $209.58 Million | +34.15% |
| 2010-12-31 | $156.23 Million | -8.98% |
| 2009-12-31 | $171.65 Million | +57.15% |
| 2008-12-31 | $109.23 Million | -16.45% |
| 2007-12-31 | $130.74 Million | +128.81% |
| 2006-12-31 | $57.14 Million | +240.28% |
| 2005-12-31 | $16.79 Million | -38.08% |
| 2004-12-31 | $27.12 Million | +447.01% |
| 2003-12-31 | $4.96 Million | -71.69% |
| 2002-12-31 | $17.51 Million | -- |